From Preclinical to Clinical First in man Study
Eliane Schutte is the CEO of Xeltis a clinical stage medtech company developing transformative implants that enable the natural creation of living and long lasting vessels and valves. Xeltis aims to meet the needs of patients and healthcare providers by offering self healing, non immunogenic implants that remain open, with a low risk of infection and a reduced need for surgical reintervention. The company recently raised €44.5 million in a Series D2 round to fund its ongoing clinical development. Eliane will speak about the challenges of entering clinical development from a young company's perspective.
Prof. Dr. Yigal Pinto is a professor at the University of Amsterdam, where he leads the Department of Experimental Cardiology in conjunction with his clinical practice in heart failure. He has initiated and executed several prospective clinical trials on heart failure management. Based on 17 years of research within his group, Yigal founded Phlox Therapeutics, a preclinical stage biotech company that develops RNA based therapies for cardiac laminopathies and therapy resistant heart failure. Yigal will reflect on the insights he has gained in preparing for clinical research, both from an investigator's and a CMO's perspective.
Join the event to learn from the experts and discuss with your colleagues during the networking drinks!
Source: RegMedXB